The case for & against
Bull & Bear analysis
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a biopharmaceutical company focused on developing therapies for rare diseases, particularly targeting cholestatic liver conditions like Progressive Familial Intrahepatic Cholestasis (PFIC) and Primary Sclerosing Cholangitis (PSC). With a robust pipeline featuring multiple clinical trials and a growing array of approved medicines, Mirum is positioned as a leader in the niche market for rare diseases. The company leverages opportunities arising from heightened disease awareness and advancements in genetic testing to expand its patient base.
Bull says
- ↑Q1 net product sales reached $160M (+43% YoY); full-year outlook raised to $660–680M.
- ↑PROGRESS trial data on Zolurgocertib showed strong FOP efficacy, enhancing approval prospects.
- ↑$421M cash reserves underpin planned US liver team expansion from 20 to 60 staff.
- ↑High momentum factors and strong institutional ownership signal continued share‐price strength.
- ↑Pipeline benefits from rising genetic testing and rare-disease awareness, driving patient growth.
- ↑Upward earnings revisions point to accelerating EPS growth and analyst confidence.
Bear says
- ↓Deeply negative earnings yield and low book-to-price ratio highlight valuation risk.
- ↓Profitability factors are weak; Q1 operating expenses surged to $949M on acquisition costs.
- ↓High short interest (~0.70) reflects skepticism ahead of key trial readouts.
- ↓Competition from Velixibat and other rare-disease therapies may erode market share.
- ↓Weak liquidity and profitability indicators raise concerns over long-term financial stability.
- ↓Regulatory or clinical setbacks in PFIC trials could delay revenue catalysts.
Investment themes with MIRM
Genetic and drug innovations driving medical breakthroughs
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- This quarter reflects the progress we've made in turning that vision into a durable, growing business. Our start was based on Liv Marley, and today we are a broader rare disease company with three approved medicines and a pipeline position to deliver multiple new therapies over the next two years.
- we are raising our full-year revenue guidance to $660 to $680 million.
- In PSC, the VISTA study of velixibat showed a significant improvement in pruritus, reinforcing the potential for velixibat to play an important role for these patients who currently have no approved medicines.
Bear points
- First quarter financials were significantly impacted by one-time expenses related to the acquisition of Blue Jay Therapeutics which closed in January of this year.
- Total operating expense for the quarter ended March 31 was $949 million, which includes $761 million in expense associated with the acquisition of Blue Jay R&D expense of $98 million, SG&A expense of $96 million, and cost of sales of $29 million.
- Expenses for the quarter included stock-based compensation, intangible amortization, and other non-cash expenses of $64 million, including $35 million of stock-based compensation expense associated with the acquisition of BlueJ.